

On 07/31/2025 Teva discontinued distribution of the **GRANIX® 480 mcg/1.6 mL (tbo-filgrastim) vial** and Teva will no longer be selling product to wholesalers, but inventory in the channel will be available to be purchased and used until inventory is exhausted. This discontinuation only affects the GRANIX 480 mcg/1.6 mL vial. However, people who already have and are using the GRANIX 480 mcg/1.6 mL vial can continue using them as prescribed until their expiration date.

Since GRANIX 480 mcg/1.6 mL vials will no longer be manufactured or distributed to wholesalers after 07/31/2025, patients and healthcare providers should consider appropriate therapeutic alternatives. Please note this discontinuation only affects the GRANIX 480 mcg/1.6 mL vials. All other dosage forms and strengths of GRANIX will still be available.

Please see full Prescribing Information for [GRANIX](#).

For medical or clinical questions please contact Teva US Medical Information at 1-888-483-8279 (M-F 9AM to 5PM EST) or by emailing USMedInfo@tevapharm.com

[LEGAL NOTICE](#) | [PRIVACY NOTICE](#)

©2025 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd.

GRX-41482 June 2025